Mvl Medisynth Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 4.50 Cr
as on 26-06-2024
- Company Age 13 Year, 27 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 25.76 Cr
as on 26-06-2024
- Revenue -3.45%
(FY 2023)
- Profit -93.74%
(FY 2023)
- Ebitda -32.51%
(FY 2023)
- Net Worth 0.94%
(FY 2023)
- Total Assets -0.43%
(FY 2023)
About Mvl Medisynth
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.50 Cr.
The company currently has active open charges totaling ₹25.76 Cr.
Neha Manthani, Eeshan Nomula, Srujan Gaddam, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999PN2011PTC174672
- Company No.
174672
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Solapur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mvl Medisynth?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neha Manthani  | Director | 01-Aug-2019 | Current |
| Eeshan Nomula | Director | 22-Aug-2017 | Current |
| Srujan Gaddam | Whole-Time Director | 22-Aug-2017 | Current |
| Tanmai Gaddam | Director | 22-Aug-2017 | Current |
Financial Performance and Corporate Structure Insights of Mvl Medisynth.
Mvl Medisynth Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.45% decrease. The company also saw a substantial fall in profitability, with a 93.74% decrease in profit. The company's net worth moved up by a moderate rise of 0.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mvl Medisynth?
In 2023, Mvl Medisynth had a promoter holding of 59.08% and a public holding of 40.92%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Svs Sourcings Private LimitedActive 6 years 7 monthsSrujan Gaddam and Tanmai Gaddam are mutual person
- Svs Medicare Private LimitedActive 14 years 4 months
Srujan Gaddam and Tanmai Gaddam are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Aug 2018 | ₹12.76 Cr | Open |
Hdfc Bank Limited Creation Date: 14 Aug 2018 | ₹13.00 Cr | Open |
How Many Employees Work at Mvl Medisynth?
Mvl Medisynth has a workforce of 43 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mvl Medisynth, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mvl Medisynth's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
